Fig. 7. In vivo anti-cancer efficacy of PTX-SA LPs. (A) Therapeutic schedule for PTX-SA LPs. (B) Tumor growth curves and (C) body weight changing curves post-injection of Taxol® and PTX-SA LPs (n = 5). (D) Tumor burden rate (n = 5) and (E) hematological and blood biochemical parameters of different formulations after treatment (the units for AST, ALT, BUN and CR are U L⁻¹, U L⁻¹, mmol L⁻¹ and μmol L⁻¹, respectively, n = 3). Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.